Elite Pharmaceuticals, Inc. (ELTP) Return on equity 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
45.4%FY2026 · since FY2017: 14.9% → 45.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 45.4% | +53.4 pp |
| FY2025 | -8.1% | -43.0 pp |
| FY2024 | 34.9% | +22.6 pp |
| FY2023 | 12.3% | -23.0 pp |
| FY2022 | 35.3% | +3.8 pp |
| FY2021 | 31.5% | +52.5 pp |
| FY2020 | -21.0% | — |
| FY2018 | -80.3% | -95.2 pp |
| FY2017 | 14.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net incomeELTP Net marginELTP Gross profitELTP Gross marginELTP Operating incomeELTP Operating marginELTP Operating cash flowELTP Free cash flowELTP Capital expendituresELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Total liabilitiesELTP Shareholders’ equityELTP overview →